Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2024-06-21 AGM Information
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
北京德恒（昆明）律师事务所关于昆药集团股份有限公司2023年年度股东大会的法律意见
AGM Information Classification · 95% confidence The document is a legal opinion from a law firm regarding the 2023 Annual General Meeting (AGM) of Kunming Pharmaceutical Group Co., Ltd. It details the convening, attendance, and voting procedures of the AGM, confirming the legality and validity of the meeting and resolutions passed. The content focuses on the AGM event itself rather than the full annual report or financial statements. The document length is short (1601 characters), and it is a legal opinion related to the AGM, not the AGM materials or the voting results announcement. Therefore, the most appropriate classification is AGM Information (AGM-R).
2024-06-21 Chinese
昆药集团2024年第四次临时股东大会会议资料
AGM Information Classification · 100% confidence The document is titled as meeting materials for the 2024 Fourth Extraordinary General Meeting of Shareholders of KPC Pharmaceuticals, Inc. It contains detailed agenda, voting procedures, and extensive information about two key proposals: acquisition of 51% equity in Kunming China Resources Shenghuo Pharmaceutical Co., Ltd. and repurchase and cancellation of restricted shares. The document includes detailed financial data, transaction background, related party relationships, asset valuation, and audit references. The content is typical of materials prepared for a shareholders meeting to inform and enable voting on significant corporate actions. It is not a transcript, earnings release, or annual report, but rather the official meeting materials for a shareholders meeting. This fits the definition of AGM Information (AGM-R). The document length and detail confirm it is the meeting materials themselves, not just an announcement or summary.
2024-06-20 Chinese
昆药集团2023年年度股东大会会议资料
AGM Information Classification · 100% confidence The document is titled as "2023 年年度股东大会会议资料" which translates to "2023 Annual General Meeting (AGM) Meeting Materials". It contains detailed agenda, reports, voting procedures, and other materials related to the 2023 Annual General Meeting of the company. The content includes the meeting time, location, participants, agenda items such as board reports, supervisory board reports, annual report summaries, financial reports, profit distribution proposals, and remuneration proposals. It also includes detailed explanations and discussions of these agenda items, as well as voting procedures and results announcement. The document is comprehensive and clearly intended as the materials shared during the AGM to inform and guide shareholders. This matches the definition of AGM Information (AGM-R). It is not a standalone annual report (10-K) or a voting results announcement (DVA), but the meeting materials for the AGM itself.
2024-06-13 Chinese
华润三九医药股份有限公司拟向昆药集团股份有限公司转让昆明华润圣火药业有限公司51%股权项目资产评估报告
Regulatory Filings
2024-06-07 Chinese
昆药集团关于收购昆明华润圣火药业51%股权暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the acquisition of 51% equity in Kunming Huarun Shenghuo Pharmaceutical Co., Ltd. by Kunming Pharmaceutical Group Co., Ltd. It includes extensive information about the transaction, including the parties involved, transaction price, payment terms, financial data of the target company, evaluation methods, and regulatory compliance. The document is not a financial report like an annual or interim report, nor is it a simple announcement of voting results or a proxy statement. It is a comprehensive disclosure of a capital transaction involving acquisition and related party transactions. The content fits best under the category of Capital/Financing Update (CAP), as it provides detailed information about a significant financing and capital structure change through acquisition.
2024-06-07 Chinese
昆药集团十届二十八次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board meeting of Kunming Pharmaceutical Group Co., Ltd. It details voting results on various proposals including acquisition, stock repurchase, policy formulation, performance assessment, and convening a shareholders meeting. The document is short (1210 characters) and focuses on board decisions and voting outcomes rather than full financial data or detailed reports. It is not an annual or interim report, nor a call transcript or earnings release. It is not a proxy solicitation or dividend notice. The content fits the category of Board/Management Information (MANG) as it announces board resolutions and management decisions.
2024-06-07 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.